NCT04342273 - A Through QT/QTc Study of KW-6356 | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

September 5, 2020

Study Completion Date

September 5, 2020

Conditions

Parkinson's Disease

Interventions

DRUG

KW-6356

KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7

DRUG

KW-6356

KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7

DRUG

Placebo

Placebo will be administered once daily at Day 1 through Day 7

DRUG

Moxifloxacin

Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.

Trial Locations (2)

Medical Co. LTA Sumida Hospital, Sumida-ku

Medical Co. LTA Fukuoka Mirai Hospital Clinical Research Center, Fukuoka

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY